The Mosaic Company
MOS
$22.80
-0.83%
The Mosaic Company is one of the world's largest producers of concentrated phosphate and potash crop nutrients, operating phosphate rock mines in the United States, potash mines in Canada, and a large fertilizer blending and distribution business in Brazil through Mosaic Fertilizantes. As a vertically integrated, mine-to-market agricultural inputs supplier, Mosaic sits at the commodity end of the global food value chain, with earnings driven by nutrient pricing, crop economics, and its own operational execution rather than by brand or pricing power. The current investor debate is dominated by a sharp deterioration in phosphate and potash realizations that has pushed the company into quarterly losses, compounded by elevated capital spending and negative trailing free cash flow, even as the dividend remains intact. Offsetting this, headlines around the closure of the Strait of Hormuz and the stranding of a large share of global fertilizer supply have revived a supply-shock thesis for North American producers with domestic inputs, and the stock's violent late-October-to-November rally reflects investors positioning for exactly that scenario.…
MOS
The Mosaic Company
$22.80
Investment Opinion: Should I buy MOS Today?
Rating: Hold, with a speculative accumulation bias for commodity-tolerant investors. The core thesis is that Mosaic is a trough-cycle phosphate and potash producer trading at 0.63x book and 5.09x EV/EBITDA, where the downside is largely priced but the earnings recovery depends on a binary Hormuz-driven nutrient price shock rather than on anything management controls. The analyst consensus of 8 Buy, 11 Hold, and 1 Sell (mean rating 2.4) with a $25.33 average target — only 13.3% above the $22.36 price — confirms the Street sees the stock as fairly valued after the November rally, not deeply undervalued.
Supporting evidence is genuinely mixed. Valuation is the strongest leg: 0.63x P/B and 0.63x P/S sit at the bottom of Mosaic's own multi-year band (P/B was 1.24x-2.09x in 2022 and 0.68x-0.95x in 2023-2024), and 5.09x EV/EBITDA is mid-cycle commodity pricing. But the operating data cuts the other way: Q3 2026 revenue of $3.10 billion fell 10.18% year-over-year, gross margin collapsed to 2.71% from 15.99%, and trailing free cash flow is -$808.3 million against $281.5 million of quarterly capex plus a $69.9 million dividend. The forward PE of 15.44x on consensus FY2026 EPS of $2.59 is actually higher than the 14.17x trailing multiple, meaning the market is already paying for a recovery that has not yet appeared in the P&L; the 3.67% dividend yield with a 51.9% payout ratio is the one concrete cash return supporting the hold case.
Three risks could invalidate the thesis: a rollback of phosphate and potash realizations toward October levels (which would push Q4 back toward the -$257.6 million to -$272.8 million loss magnitude of Q1-Q2), a dividend cut or capex reduction forced by negative free cash flow, and fading sell-side support after RBC's October 5 downgrade to Sector Perform and the cluster of Neutral ratings from UBS, CIBC, Barclays, Mizuho, and Morgan Stanley. This Hold would upgrade to Buy on evidence of two consecutive quarters of positive operating income with gross margin back above 10%, or on a decisive break above the $26.53 September high; it would downgrade to Sell on a loss of the $16.99 52-week low or a dividend cut. Verdict: fairly valued to modestly undervalued on asset-based metrics, but expensive relative to current cash generation — a trough-cycle value stock, not a bargain.
Sign up to view all
MOS 12-Month Price Forecast
Mosaic is a classic trough-cycle commodity call where the valuation floor is real but the earnings recovery is not yet visible in the financials. The 0.63x book and 5.09x EV/EBITDA multiples already discount a severe downturn, and the narrowing loss trajectory from -$257.6 million in Q1 to -$72.1 million in Q3 suggests the margin trough is behind the company — but a 2.71% gross margin and -$808.3 million of trailing free cash flow mean the dividend and capex program are being funded on faith. The 13.3% upside to the $25.33 average target is too thin to compensate for a $17.00 low target that implies roughly 24% downside, and the 11 Hold ratings plus RBC's October downgrade show the Street has not resolved the durability question either. I would upgrade to bullish if Q4 2026 delivers positive operating income with gross margin above 10% and the Hormuz disruption persists into 2027, or if the stock breaks decisively above the $26.53 September high on volume. I would downgrade to bearish on a loss of the $16.99 52-week low, a dividend cut, or evidence that phosphate and potash realizations are rolling back toward October levels.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Mosaic Company's 12-month outlook, with a consensus price target around $25.11 and implied upside of +10.1% versus the current price.
Average Target
$25.11
20 analysts
Implied Upside
+10.1%
vs. current price
Analyst Count
20
covering this stock
Price Range
$17 - $34
Analyst target range
Coverage is solid with 18 analysts, and the distribution of 8 Buy, 11 Hold, and 1 Sell produces a consensus recommendation of "buy" with a mean rating of 2.4, which in practice reads as a cautiously constructive hold-to-buy stance rather than conviction. The average target price of $25.33 implies roughly 13.3% upside from the current $22.36, a modest spread that suggests the Street sees the stock as fairly valued after the recent rally rather than deeply undervalued. Consensus fiscal 2026 EPS of $2.59 (range $2.21 to $3.10) on revenue of $11.7 billion underpins those targets, and the fact that the average target sits only modestly above the post-gap price indicates much of the near-term recovery is already reflected.
The target range of $17.00 to $34.00 is wide — a 100% spread from low to high — which signals genuine disagreement about the durability of fertilizer prices and Mosaic's cost position. The $34.00 high target implies a full re-rating toward the upper end of the historical book-value band and a meaningful phosphate/potash price recovery, likely tied to the Hormuz supply disruption thesis; the $17.00 low target essentially prices a return to the October lows and assumes margin compression persists or worsens. Institutional actions skew negative on the margin: RBC Capital downgraded to Sector Perform from Outperform on October 5, Freedom Broker moved to Sell in August before reversing to Hold on November 2, and the majority of recent actions (UBS, CIBC, Barclays, Mizuho, Morgan Stanley) are Neutral or Equal Weight — a pattern of fading enthusiasm that argues for treating the consensus "buy" label with skepticism.
Bulls vs Bears: MOS Investment Factors
The bear case currently has the stronger evidentiary base: three consecutive quarterly losses, a 2.71% gross margin, -$808.3 million of trailing free cash flow, and a 10.18% revenue decline are hard facts, whereas the bull case rests largely on a binary geopolitical supply shock and a valuation floor that has already been breached once this year. That said, the bull argument is not frivolous — 0.63x book, 5.09x EV/EBITDA, and a narrowing loss trajectory mean the downside from here is more about duration of the trough than about discovering a new lower valuation regime. The single most important tension is whether the Hormuz-driven fertilizer supply disruption proves durable enough to lift phosphate and potash realizations before the dividend and capex program exhaust the balance sheet's patience; if prices normalize, the 15.44x forward PE on $2.59 of EPS is cheap, and if they do not, the $17.00 low target becomes the magnet. Analyst positioning (11 Holds, a $17-$34 target range) confirms the Street itself has not resolved this question.
Bullish
- Trough valuation on book and sales: At 0.63x price-to-book and 0.63x price-to-sales, MOS trades at the bottom of its own multi-year band (P/B was 1.24x-2.09x in 2022 and 0.68x-0.95x in 2023-2024). EV/EBITDA of 5.09x is consistent with a mid-cycle commodity producer priced for a downturn, meaning much of the earnings recession is already discounted.
- Hormuz supply shock revives pricing thesis: The closure of the Strait of Hormuz has stranded roughly a third of global fertilizer supply, a direct margin opportunity for a producer with domestic US phosphate rock and Canadian potash. The stock's 17% single-session gap from $18.42 to $21.62 on 12.3 million shares shows the market repricing this scenario in real time.
- Losses narrowing sharply quarter-over-quarter: Net loss improved from -$257.6 million in Q1 2026 to -$272.8 million in Q2 and then -$72.1 million in Q3, while operating income swung from -$355 million to -$96.6 million. Gross margin recovered from 7.6% in Q2 to a still-weak 2.71% in Q3, but the direction of travel suggests the margin trough is behind the company.
- Analyst targets imply double-digit upside: The $25.33 average target sits 13.3% above the $22.36 price, with a high target of $34.00 implying roughly 52% upside if nutrient prices fully normalize. Consensus FY2026 EPS of $2.59 against a forward PE of 15.44x shows the Street expects earnings to recover from the depressed trailing base.
Bearish
- Profitability has collapsed to near zero: Q3 2026 gross margin of 2.71% compares with 15.99% a year earlier, and the company posted a -$72.1 million net loss versus a $411.4 million profit in Q3 2025. Trailing ROE of 4.47% and ROA of -0.06% confirm the business is currently earning below its cost of capital.
- Negative free cash flow and heavy capex: Trailing free cash flow is -$808.3 million, and Q3 operating cash flow of $284.4 million barely covered $281.5 million of capex, leaving nothing for the $69.9 million dividend. The 3.67% yield with a 51.9% payout ratio is only sustainable if nutrient prices recover or assets are sold.
- Revenue declining with no inflection: Q3 2026 revenue of $3.10 billion fell 10.18% year-over-year, following $2.82 billion in Q2 and $3.00 billion in Q1 — a flat-to-down sequential pattern. Phosphates ($1.29 billion) and Fertilizantes ($1.25 billion) together are roughly 82% of sales, concentrating the risk in two price-sensitive segments.
- Analyst enthusiasm is fading, not building: Despite a consensus 'buy' label, the distribution is 8 Buy, 11 Hold, and 1 Sell with a mean rating of 2.4, and RBC downgraded to Sector Perform on October 5 while UBS, CIBC, Barclays, Mizuho, and Morgan Stanley sit at Neutral or Equal Weight. The $17.00 low target implies roughly 24% downside from the current price.
MOS Technical Analysis
Mosaic is in a damaged but stabilizing downtrend: the stock is down 10.27% over the past year and 10.63% year-to-date, and at $22.36 it sits at roughly 35% of its 52-week range of $16.99 to $32.25, having suffered a maximum drawdown of -51.23% from its highs. That positioning near the lower third of the range tells you the market has already priced a severe earnings recession, but the failure to make a lower low below $16.99 in late October suggests the selling may have exhausted itself rather than confirming a falling-knife breakdown. The 52-week high of $32.25 remains 44% above the current price, so any recovery is, for now, a counter-trend trade rather than a resumption of a primary uptrend.
Short-term momentum has turned decisively positive and is diverging sharply from the longer-term trend: the stock is up 11.97% over the past month versus a 3.04% decline over three months and a 0.77% gain over six months, with a relative strength reading of +16.96 percentage points against the S&P 500's -4.99% one-month move. The most striking feature of the tape is the single-session gap from $18.42 on November 3 to $21.62 on November 4, a roughly 17% one-day move on heavy volume of 12.3 million shares, which is characteristic of a news- or earnings-driven repricing rather than organic accumulation. That kind of vertical move typically invites short-term consolidation, and with a short ratio of 3.69 days-to-cover there is a plausible squeeze component that could fade once positioning normalizes.
Key technical levels are well defined: support sits at the $16.99 52-week low, with a secondary shelf around $17.68-$18.42 where the October basing occurred, while resistance is the $24.41-$26.53 zone from the August-September highs, well below the $32.25 annual peak. A decisive break above $26.53 would confirm a higher-high structure and validate the supply-shock thesis, whereas a loss of $16.99 would signal that the fundamental deterioration is overwhelming any commodity tailwind. With a beta of 0.858 the stock is roughly 14% less volatile than the market on a trailing basis, which argues for somewhat larger position sizing than a high-beta cyclical would warrant, though the -51.23% drawdown is a reminder that idiosyncratic commodity risk dominates the low beta in practice.
Beta
0.86
0.86x market volatility
Max Drawdown
-51.2%
Largest decline past year
52-Week Range
$17-$32
Price range past year
Annual Return
-11.3%
Cumulative gain past year
| Period | MOS Return | S&P 500 |
|---|---|---|
| 1m | +21.0% | -2.4% |
| 3m | +4.7% | -2.3% |
| 6m | +4.8% | +2.8% |
| 1y | -11.3% | +11.3% |
| ytd | -8.9% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MOS Fundamental Analysis
The revenue trajectory has deteriorated materially: fiscal Q3 2026 revenue of $3.10 billion fell 10.18% year-over-year from $3.45 billion, following Q2 revenue of $2.82 billion and Q1 revenue of $3.00 billion, a sequential pattern that shows no growth inflection. Segment data for the quarter shows Phosphates at $1.29 billion, Mosaic Fertilizantes at $1.25 billion, and Potash at $643 million, meaning the phosphate and Brazilian distribution businesses together account for roughly 82% of sales and are the primary swing factors in the earnings equation. The consensus fiscal 2026 revenue estimate of $11.7 billion (range $10.4 billion to $13.5 billion) implies continued top-line pressure, and with a 10.18% YoY decline already in hand, the investment case now hinges entirely on price recovery rather than volume growth.
Profitability has collapsed: Q3 2026 net income was -$72.1 million (-$0.23 per diluted share) on a gross margin of just 2.71%, a dramatic compression from Q3 2025's $411.4 million profit and 15.99% gross margin, and from Q1 2025's 18.63% gross margin. The quarterly progression is ugly — Q1 2026 lost $257.6 million, Q2 lost $272.8 million, and Q3 lost $72.1 million — though the narrowing loss and the swing from -$355 million to -$96.6 million in operating income suggests the worst of the margin trough may be behind the company. The trailing net margin of 4.49% and operating margin of 8.71% are far below the 15%+ gross margins Mosaic earned in 2022-2023, underscoring how much of the current valuation debate is really a bet on nutrient price normalization.
Balance sheet and cash flow are the weak link: trailing free cash flow is -$808.3 million against capital expenditures of $281.5 million in Q3 alone, and the Q3 operating cash flow of $284.4 million was insufficient to cover $281.5 million of capex plus $69.9 million of dividends. Debt-to-equity of 0.437 and a current ratio of 1.315 are manageable but not comfortable, while ROE of 4.47% and ROA of -0.06% confirm the business is currently earning below its cost of capital. The dividend yield of 3.67% with a payout ratio of 51.9% is a meaningful cash commitment that, combined with negative free cash flow, raises the question of whether the payout is sustainable without a price recovery or asset sales.
Quarterly Revenue
$3.1B
2026-09
Revenue YoY Growth
-10.2%
YoY Comparison
Gross Margin
2.7%
Latest Quarter
Free Cash Flow
$-808300000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MOS Overvalued?
Because trailing net income is positive at the consolidated level (EPS of $0.07), the PE ratio is the appropriate primary metric, and at 14.17x trailing it looks optically cheap — but that multiple is distorted by a tiny earnings base and masks the fact that the last three quarters were all losses. The forward PE of 15.44x on consensus EPS of $2.59 is actually higher than the trailing multiple, which is unusual and signals that the market expects earnings to normalize upward from a depressed base rather than compound from current levels; the PEG ratio of 0.068 is essentially meaningless given the near-zero earnings denominator.
On the metrics that are more reliable for a cyclical at a trough, Mosaic screens cheap: price-to-book of 0.63x, price-to-sales of 0.63x, EV/sales of 1.10x, and EV/EBITDA of 5.09x, all consistent with a mid-cycle commodity producer trading at a discount. The 0.63x book multiple is the key tell — the market is valuing the asset base at a 37% discount to stated equity, which is typical when investors doubt the durability of through-cycle returns on those assets. Without a clean industry-average comparison in the provided data, the most defensible read is that these multiples sit at the low end of Mosaic's own historical band rather than at a premium to peers.
Historical context reinforces the trough-valuation picture: Mosaic's price-to-book ranged from 1.24x-2.09x in 2022, 0.68x-0.95x through 2023-2024, and has compressed to 0.59x-0.69x across 2026 quarters, while price-to-sales has fallen from 3.3x-6.2x in 2022 to 0.63x today. The stock is at or near the bottom of its own multi-year valuation band on both book and sales, which historically has marked accumulation zones for this name — but it can also reflect genuine fundamental deterioration, and the negative $808 million trailing free cash flow argues the latter cannot be dismissed.
PE
14.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 4x~12x
vs. Industry Avg
14.2x
Industry PE ~14.2x*
EV/EBITDA
5.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute and quantifiable. Trailing free cash flow of -$808.3 million against Q3 capex of $281.5 million means the company is funding capital spending and a $69.9 million quarterly dividend from operating cash flow of just $284.4 million, leaving essentially no buffer; the 3.67% yield and 51.9% payout ratio are therefore at risk if nutrient prices stay depressed. Gross margin of 2.71% in Q3 2026 versus 15.99% a year earlier shows how little cushion exists between revenue and cost of goods, and with Phosphates plus Fertilizantes at roughly 82% of the $3.10 billion quarterly revenue, a further leg down in either phosphate or Brazilian distribution pricing would push losses back toward the Q1-Q2 2026 magnitude of -$257.6 million to -$272.8 million. Debt-to-equity of 0.437 and a current ratio of 1.315 are manageable but leave limited room to lever up through a prolonged trough. Market and competitive risks center on valuation compression and commodity cyclicality. The stock carries a beta of 0.858, so it is roughly 14% less volatile than the market on a trailing basis, but that understates the idiosyncratic risk: the -51.23% maximum drawdown occurred despite the low beta, because fertilizer realizations, not the equity market, drive the shares. The recent 17% one-day gap on 12.3 million shares was a headline-driven repricing tied to the Hormuz closure, and such moves are prone to retracement once the short ratio of 3.69 days-to-cover normalizes; RBC's October 5 downgrade to Sector Perform and the cluster of Neutral ratings from UBS, CIBC, Barclays, Mizuho, and Morgan Stanley suggest sell-side support is thinning. A rotation away from commodity equities or a resolution of the Hormuz disruption would remove the primary near-term catalyst. The worst-case scenario is a specific chain: the Hormuz disruption proves temporary, phosphate and potash realizations roll back toward October levels, Q4 2026 prints another loss, and the dividend is cut or capex is slashed, forcing the market to reprice MOS toward the $17.00 analyst low and the $16.99 52-week low. From $22.36, that is roughly -24% to -25%, and a break below $16.99 would open the door to the lower end of the historical book-value band, implying losses in the -30% to -35% range from current levels. The -51.23% max drawdown is the empirical reminder of how far this name can fall when the commodity cycle turns against it.
FAQ
Ranked by severity: first, liquidity and dividend sustainability — trailing free cash flow of -$808.3 million against $281.5 million of quarterly capex and a $69.9 million quarterly dividend means the payout (51.9% of earnings, 3.67% yield) could be cut if prices stay depressed, which would likely force a re-rating toward the $17.00 low target. Second, commodity price risk — phosphate and potash realizations rolling back toward October levels would push quarterly losses back toward the -$257.6 million to -$272.8 million magnitude of Q1-Q2 2026, and with Phosphates plus Fertilizantes at roughly 82% of revenue, there is little diversification buffer. Third, catalyst reversal — the November 4 one-day 17% gap on 12.3 million shares was driven by the Hormuz supply disruption, and a reopening or de-escalation would remove the supply premium; the 3.69-day short ratio suggests a squeeze component that could unwind. Fourth, sentiment and valuation compression — RBC's October 5 downgrade to Sector Perform plus Neutral ratings from UBS, CIBC, Barclays, Mizuho, and Morgan Stanley show thinning sell-side support, and the -51.23% max drawdown despite a 0.858 beta is a reminder that idiosyncratic commodity risk dominates market beta here.
The scenario framework assigns 50% to a base case of $23-$27, 25% to a bull case of $30-$34, and 25% to a bear case of $16.99-$19.00. The base case is most likely: it assumes nutrient prices hold modestly above October troughs, FY2026 EPS lands near the $2.59 consensus midpoint within the $2.21-$3.10 range, and the stock trades near the $25.33 average target — a modest re-rating from 0.63x book without a return to the 2022-2023 multiple band. The bull case requires the Hormuz disruption to persist into 2027, lifting gross margin back above 10% and FY2027 EPS above $3.10, which would justify the $34.00 high target. The bear case assumes supply normalizes, Q4 2026 prints another loss, and a dividend cut or capex reduction forces a retest of the $16.99 52-week low. The key assumption behind the base case is that the supply premium fades gradually rather than collapsing.
On asset-based metrics Mosaic is modestly undervalued: 0.63x price-to-book means the market values equity at a 37% discount to stated book, versus a 1.24x-2.09x band in 2022 and 0.68x-0.95x in 2023-2024, and 0.63x price-to-sales compares with 3.3x-6.2x in 2022. EV/EBITDA of 5.09x and EV/sales of 1.10x are consistent with a mid-cycle commodity producer priced for a downturn. On earnings, however, the picture inverts: the 14.17x trailing PE rests on a near-zero $0.07 EPS base, and the 15.44x forward PE on consensus $2.59 is actually higher than trailing, meaning the market is already paying for a recovery that has not appeared in the P&L. The 0.068 PEG ratio is not meaningful given the depressed denominator. Net verdict: fairly valued to modestly undervalued on assets, expensive relative to current cash generation — the market is pricing a normalization of phosphate and potash realizations rather than continued deterioration.
The risk/reward is balanced rather than compelling at $22.36. Upside to the $25.33 average analyst target is only 13.3%, while the $17.00 low target implies roughly 24% downside — a roughly 0.55:1 reward-to-risk ratio that does not compensate for the binary nature of the nutrient-price catalyst. The valuation floor is genuine (0.63x book, 0.63x sales, 5.09x EV/EBITDA, all at the bottom of Mosaic's multi-year band), and the loss trajectory is improving from -$257.6 million in Q1 to -$72.1 million in Q3, which limits how much further the equity should fall absent a fresh shock. But a 2.71% gross margin and -$808.3 million of trailing free cash flow mean the 3.67% dividend is being funded on faith, and 11 of 18 analysts rate the stock a Hold. It is a reasonable speculative accumulation for commodity-tolerant investors with a 2-3 year horizon who want cyclical fertilizer exposure at a trough multiple; it is a poor buy for anyone needing near-term earnings visibility or a reliable income stream.
MOS is best suited to a medium-to-long-term holding period of at least 18-24 months, because the thesis depends on a commodity cycle turn that is not yet visible in reported earnings — three consecutive 2026 quarterly losses and a 2.71% gross margin mean the recovery will take multiple quarters to show up in the P&L. The 0.858 beta is below the market, which argues against treating it as a high-volatility trading vehicle, but the -51.23% max drawdown and the 17% single-session gap on November 4 show that headline-driven volatility is high in practice, making short-term trading a bet on geopolitical headlines rather than fundamentals. The 3.67% dividend yield with a 51.9% payout ratio offers some carry, but its sustainability is unproven given negative free cash flow, so it should not be relied on as an income holding. A concrete minimum holding period of two years aligns with the base-case assumption that FY2027 EPS recovers toward the $2.59-$3.10 consensus range and the stock re-rates toward the $25.33 average target.